X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16) 16
female (15) 15
oncology (15) 15
aged (13) 13
middle aged (13) 13
breast cancer (12) 12
adult (11) 11
chemotherapy (11) 11
cancer (10) 10
index medicus (10) 10
young adult (8) 8
breast neoplasms - drug therapy (7) 7
breast neoplasms - pathology (7) 7
medicine & public health (7) 7
prognosis (7) 7
chemotherapy, adjuvant (6) 6
clinical trials (6) 6
epirubicin (6) 6
immunohistochemistry (6) 6
male (6) 6
anthracyclines (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
carcinoma (5) 5
cooperative oncology group (5) 5
greece (5) 5
health aspects (5) 5
hospitals (5) 5
medicine (5) 5
radiotherapy (5) 5
research article (5) 5
survival (5) 5
adjuvant treatment (4) 4
analysis (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
care and treatment (4) 4
dense sequential chemotherapy (4) 4
disease-free survival (4) 4
drug therapy (4) 4
kaplan-meier estimate (4) 4
neoplasm staging (4) 4
paclitaxel (4) 4
randomized phase-iii (4) 4
risk factors (4) 4
tissue microarrays (4) 4
treatment outcome (4) 4
acquisitions & mergers (3) 3
aged, 80 and over (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
breast neoplasms - metabolism (3) 3
breast neoplasms - mortality (3) 3
cancer patients (3) 3
cancer therapies (3) 3
dose-response relationship, drug (3) 3
drug administration schedule (3) 3
fluorouracil - administration & dosage (3) 3
genes (3) 3
genetic aspects (3) 3
lymphatic metastasis (3) 3
medical research (3) 3
overexpression (3) 3
patient outcomes (3) 3
product development (3) 3
proportional hazards models (3) 3
recommendations (3) 3
research (3) 3
surgery (3) 3
survival analysis (3) 3
therapy (3) 3
tumors (3) 3
abdominal surgery (2) 2
adjuvant chemotherapy (2) 2
anatomy (2) 2
anthracycline (2) 2
antigens, neoplasm - genetics (2) 2
antineoplastic agents - therapeutic use (2) 2
biological markers (2) 2
biology and life sciences (2) 2
biomarkers, tumor - genetics (2) 2
breast (2) 2
breast - pathology (2) 2
breast neoplasms - diagnosis (2) 2
breast neoplasms - genetics (2) 2
breast tumors (2) 2
cancer research (2) 2
cancer treatment (2) 2
cancers and neoplasms (2) 2
cardiac surgery (2) 2
cell biology (2) 2
chemotherapy-induced febrile neutropenia - epidemiology (2) 2
clinical medicine (2) 2
colon cancer (2) 2
colonic neoplasms - pathology (2) 2
colorectal cancer (2) 2
cyclophosphamide (2) 2
discontinuation (2) 2
epirubicin - administration & dosage (2) 2
epstein-barr virus (2) 2
epstein-barr-virus (2) 2
erbb-2 protein (2) 2
feasibility studies (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 08/2017, Volume 12, Issue 8, p. e0180489
Background-Aim To evaluate the prognostic role of elaborate molecular clusters encompassing cyclin D1, cyclin E1, p21, p27 and p53 in the context of various... 
OVEREXPRESSION | COOPERATIVE ONCOLOGY GROUP | PROGNOSTIC-FACTOR | EPIRUBICIN | RANDOMIZED PHASE-III | MULTIDISCIPLINARY SCIENCES | DENSE SEQUENTIAL CHEMOTHERAPY | INHIBITORS | P21 | P27(KIP1) | Immunohistochemistry | Prognosis | Cyclin-Dependent Kinase Inhibitor p27 - analysis | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Triple Negative Breast Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Young Adult | Cyclin D1 - analysis | Tumor Suppressor Protein p53 - analysis | Cyclin-Dependent Kinase Inhibitor p21 - analysis | Breast - drug effects | Breast Neoplasms - pathology | Triple Negative Breast Neoplasms - diagnosis | Cyclin E - analysis | Survival Analysis | Triple Negative Breast Neoplasms - pathology | Adult | Female | Aged | Breast Neoplasms - diagnosis | Oncogene Proteins - analysis | Breast - pathology | Usage | Analysis | Cell cycle | Clinical trials | Breast cancer | Research | Health sciences | GTP-binding protein | Regulators | Laboratories | Molecular clusters | p53 Protein | Oncology | Paraffin | Cyclin D1 | Kinases | Tissues | Cancer therapies | Formaldehyde | Cell adhesion & migration | Proteins | Medical research | Cyclin-dependent kinases | Clustering | Medicine | Pathology | Cyclin-dependent kinase inhibitor p21 | Hospitals | Medical prognosis | Breast | Tumors | Cancer | Apoptosis
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2018, Volume 13, Issue 7, p. e0200302
Several studies support an important role of angiogenesis in breast cancer growth and metastasis. The main objectives of the study were to investigate the... 
CLINICAL ONCOLOGY/COLLEGE | RECOMMENDATIONS | MULTIDISCIPLINARY SCIENCES | FACTOR RECEPTOR 2 | LYMPHANGIOGENESIS | FACTOR EXPRESSION | VEGF-C | TUMOR ANGIOGENESIS | CARCINOMA | AMERICAN SOCIETY | ENDOTHELIAL GROWTH-FACTOR | Neovascularization, Pathologic - mortality | Neovascularization, Pathologic - diagnosis | Prognosis | Humans | Middle Aged | Proportional Hazards Models | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor Receptor-3 - metabolism | Breast - metabolism | Breast Neoplasms - metabolism | Young Adult | Breast Neoplasms - pathology | Vascular Endothelial Growth Factor C - metabolism | Adult | Breast Neoplasms - mortality | Female | Aged | Breast Neoplasms - diagnosis | Neovascularization, Pathologic - metabolism | Breast - pathology | Proteins | Immunohistochemistry | Care and treatment | Cancer patients | Chemotherapy | Patient outcomes | Breast cancer | Vascular endothelial growth factor | Cancer | Health sciences | Laboratories | C protein | Oncology | Paraffin | Kinases | Subgroups | Metastases | Angiogenesis | Signal transduction | Receptors | Epidermal growth factor | Paraffins | Medical research | Parameters | Statistical tests | Gene expression | Patients | ErbB-2 protein | Survival | Vascular endothelial growth factor receptors | Medicine | Pathology | Gene amplification | Hospitals | Anthracycline | Medical prognosis | Biomarkers | Breast | Tumors
Journal Article
BMC Medicine, ISSN 1741-7015, 01/2011, Volume 9, Issue 1, pp. 10 - 10
Background: Colon cancer is a public health problem worldwide. Adjuvant chemotherapy after surgical resection for stage III colon cancer has been shown to... 
1ST-LINE TREATMENT | PLUS LEUCOVORIN | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | PERSPECTIVES | CAMPTOTHECINS | OXALIPLATIN | METASTATIC COLORECTAL-CANCER | FOLFIRI | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Greece | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Adult | Camptothecin - administration & dosage | Female | Leucovorin - therapeutic use | Chemotherapy, Adjuvant | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colonic Neoplasms - pathology | Aged | Neoplasm Staging | Chemotherapy | Usage | Colon cancer | Patient outcomes | Leucovorin | Drug therapy, Combination | Drug therapy | Health aspects | Fluorouracil | Cancer | Medical imaging | Heart attacks | Statistical analysis | Mortality | Colorectal cancer | Clinical trials | Histology | Cancer therapies | Manuscripts | Medicine | Hospitals | Tomography | Clinical medicine | Acquisitions & mergers | Index Medicus
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 4/2012, Volume 132, Issue 2, pp. 609 - 619
Journal Article
BMC Cancer, ISSN 1471-2407, 07/2014, Volume 14, Issue 1, pp. 515 - 515
Journal Article
BMC Cancer, ISSN 1471-2407, 03/2013, Volume 13, Issue 1, pp. 163 - 163
Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other... 
TOP2A | Adjuvant chemotherapy | Anthracyclines | Predictive factors | TopoIIa | Breast cancer | HER2 | Taxanes | Prognostic factors | TOPOISOMERASE-II | RANDOMIZED-TRIALS | IN-SITU HYBRIDIZATION | TISSUE MICROARRAYS | TOP2A STATUS | ONCOLOGY | COPY NUMBER CHANGES | PREDICTIVE BIOMARKERS | CHROMOSOME-17 POLYSOMY | HER2 STATUS | DENSE SEQUENTIAL CHEMOTHERAPY | Immunohistochemistry | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Breast Neoplasms - metabolism | DNA-Binding Proteins - metabolism | Young Adult | Poly-ADP-Ribose Binding Proteins | Clinical Trials, Phase III as Topic | Anthracyclines - administration & dosage | Neoplasm Grading | Antigens, Neoplasm - metabolism | Biomarkers, Tumor - metabolism | Adult | Female | Odds Ratio | Antigens, Neoplasm - genetics | DNA Topoisomerases, Type II - metabolism | In Situ Hybridization, Fluorescence | Gene Dosage | DNA-Binding Proteins - genetics | Breast Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Breast Neoplasms - genetics | Centromere | Chromosomes, Human, Pair 17 | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Chromosome Aberrations | Breast Neoplasms - mortality | DNA Topoisomerases, Type II - genetics | Aged | Biomarkers, Tumor - genetics | Neoplasm Staging | Research | Drug therapy | Biological markers | Analysis | Care and treatment | Genes | Adjuvant treatment | Clinical trials | Fluorescence | Radiotherapy | Product development | Genetic aspects | Health aspects | Cancer
Journal Article
SUPPORTIVE CARE IN CANCER, ISSN 0941-4355, 04/2019, Volume 27, Issue 4, pp. 1449 - 1457
Journal Article
Journal Article
Anticancer Research, ISSN 0250-7005, 06/2017, Volume 37, Issue 6, pp. 2947 - 2957
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 2/2008, Volume 107, Issue 3, pp. 431 - 441
Journal Article